Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene

1. A double-stranded ribonucleic acid (dsRNA), wherein said dsRNA comprises a sense strand 15-30 nucleotides in length and an antisense strand 15-30 nucleotides in length, the antisense strand comprising a region of complementarity which is complementary to at least 15 nucleotides of SEQ ID NO:179.

2. The dsRNA of claim 1 , wherein the sense strand comprises at least 15 contiguous nucleotides of SEQ ID NO:179.

3. The dsRNA of claim 1 , wherein the antisense strand comprises at least 15 contiguous nucleotides of SEQ ID NO:180.

4. The dsRNA of claim 1 , wherein the sense strand consists of the nucleotide sequence of SEQ ID NO:179 and the antisense strand consists of the nucleotide sequence of SEQ ID NO:180.

5. The dsRNA of claim 1 , wherein the sense strand consists of SEQ ID NO:23 and the antisense strand consists of SEQ ID NO:24 and each strand is modified as follows to include a 2′-O-methylcytidine-3′-phosphate as indicated by a lower case letter “c” and a 2′-O-methyluridine-3′-phosphate as indicated by a lower case letter “u”: SEQ ID NO:23 cAuGcucGGGGGAAcuAuGdTdT and SEQ ID NO:24 cAuAGUUCCCCCGAGcAUGdTdT.

6. The dsRNA of claim 1 , comprising at least one modified nucleotide.

7. The dsRNA of claim 1 , comprising at least one modified nucleotide selected from the group consisting of: a 2′-O-methyl modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group, a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group, a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, a 2′-amino-modified nucleotide, a 2′-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a 2′-O-methylcytidine-5′-phosphate, a 2′-O-methyluridine-5′-phosphate, and a non-natural base comprising nucleotide.

8. The dsRNA of claim 1 , wherein each strand is 21 nucleotides in length.

9. The dsRNA of claim 1 , comprising a dTdT overhang on the 3′ end of each strand.

10. The dsRNA of claim 1 , wherein the region of complementarity is 19-21 nucleotides in length.

11. The dsRNA of claim 1 , wherein the dsRNA is conjugated to a ligand.

12. The dsRNA of claim 1 , wherein the dsRNA is formulated in a lipid formulation.

13. The dsRNA of claim 1 , wherein administration of the dsRNA to a cell results in 97%, 95%, 92%, 89%, or 74% inhibition of SAA mRNA expression as measured by a real time PCR assay or 89%, 87%, 83%, 68%, or 54% inhibition of SAA mRNA expression as measured by a branched DNA assay or 100%, 99%, or 93% inhibition of SAA protein expression as measured by a ELISA assay compared to an siRNA control; or administration of the dsRNA to a mouse reduces SAA protein expression by about 80% compared to an siRNA control.

14. The dsRNA of claim 1 , wherein the dsRNA has an IC50 of less than 10 pM.

15. A cell comprising the dsRNA of claim 1 .

16. A vector comprising a nucleotide sequence encoding at least one strand of the dsRNA of claim 1 .

17. A cell comprising the vector of claim 16 .

18. A pharmaceutical composition for inhibiting expression of an SAA gene comprising the dsRNA of claim 1 .

19. A method of inhibiting SAA expression in a cell, the method comprising:

(a) introducing into the cell the dsRNA of claim 1 ; and

(b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of an SAA gene, thereby inhibiting expression of the SAA gene in the cell.

20. The method of claim 19 , wherein the method is performed in-vitro.

21. The dsRNA of claim 12 , wherein the lipid formulation is an LNP01 formulation.